Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05190457 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 100 mg PF-05190457 | EXPERIMENTAL | Three fasted treatments and fed with the short-duration osmotic capsule |
| 100 mg PF - 05190457 | EXPERIMENTAL | Three fasted treatments and fed with the long-duration osmotic capsule |
| Active | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-05190457 | DRUG | 100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state |
| Placebo | DRUG | Single Dose Placebo |
Inclusion Criteria: * Healthy males and females of non-childbearing potential between ages of 21 and 55 years, BMI of 17.5 to 30.5 kg/m\^2, and weight above 50 kg. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, car...
PF-05190457 is an investigational small molecule being developed for Type 2 Diabetes Mellitus. It is in Phase 1 clinical development and has not been approved by regulatory authorities. Studies have been conducted in healthy volunteers to evaluate the drug's safety and pharmacokinetics.
PF-05190457 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials for the treatment of Type 2 Diabetes Mellitus.
PF-05190457 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is investigational and has not received FDA approval. It is being studied for potential use in Type 2 Diabetes Mellitus.
PF-05190457 has been studied in two completed Phase 1 trials. NCT01247896 was a single dose escalation study in 26 healthy volunteers in Belgium. NCT01522807 evaluated three formulations of the drug in 16 healthy volunteers in Singapore. Both trials were randomized, double-blind, and controlled.
PF-05190457 is the primary identifier for this investigational compound. No alternative names have been reported in clinical trial registrations. The drug is being studied under this identifier in Phase 1 trials for Type 2 Diabetes Mellitus.